NCT07660198

Study to Learn About Safety, Tolerability, and Immune Response of a Catch-up Pneumococcal Vaccine in Children and Adolescents

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2026-06-15Est. Completion: 2027-12-02

Enrollment target: 1,200 participants

Locations

Alabama Clinical Therapeutics, LLC Birmingham Pediatric Associates, Birmingham, Alabama, United States
UAB Child Health Research Unit (CHRU), Birmingham, Alabama, United States
Lakeview Clinical Research, LLC, Guntersville, Alabama, United States
Apex Research Group, Fair Oaks, California, United States
Orange County Research Institute, Ontario, California, United States
Children's Hospital Colorado, Aurora, Colorado, United States
Riveldi and Associates, Miami Lakes, Florida, United States
Indago Research & Health Center, Inc, Miami Lakes, Florida, United States
South Tampa Center for Advanced Healthcare- USF Health, Tampa, Florida, United States
USF Health, Tampa, Florida, United States
USF Health Department of Pediatrics The Chalsty Clinics at the Curran Children's Health Center (CMS), Tampa, Florida, United States
Children's Health Center, Tampa, Florida, United States
Medical Research Partners, Ammon, Idaho, United States
Bingham Memorial Hospital, Blackfoot, Idaho, United States
ASR, LLC, Boise, Idaho, United States

Pneumococcal Disease

The purpose of this study is to learn about the safety of a new pneumococcal vaccine and how the new pneumococcal vaccin…

Estero, United StatesEst. completion Dec 30, 2028

Pneumococcal Disease

The purpose of this study is to learn about the safety of the 20-valent pneumococcal conjugate vaccine (20vPnC) among ad…

Nanning, ChinaEst. completion Jun 10, 2027

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.